Related references
Note: Only part of the references are listed.Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy
Chizu Nonomura et al.
IMMUNOLOGY LETTERS (2019)
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Brian C. Miller et al.
NATURE IMMUNOLOGY (2019)
T cell stemness and dysfunction in tumors are triggered by a common mechanism
Suman Kumar Vodnala et al.
SCIENCE (2019)
Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice
Chang-Yu Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
M. Messaoudene et al.
ANNALS OF ONCOLOGY (2019)
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Fangjun Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Elisabeth Perez-Ruiz et al.
NATURE (2019)
The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
A. Elkrief et al.
ANNALS OF ONCOLOGY (2019)
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Yan Zhang et al.
CELL RESEARCH (2019)
Immune checkpoint inhibitor combinations: Current efforts and important aspects for success
Edo Kon et al.
DRUG RESISTANCE UPDATES (2019)
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
Francesca Alfei et al.
NATURE (2019)
TOX is a critical regulator of tumour-specific T cell differentiation
Andrew C. Scott et al.
NATURE (2019)
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Omar Khan et al.
NATURE (2019)
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
Vivek Verma et al.
NATURE IMMUNOLOGY (2019)
On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment
Grazia R. Tundo et al.
CHEMOTHERAPY (2019)
Neoantigen quality, not quantity
Nicholas McGranahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
Lei Wu et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Combinatorial prediction of marker panels from single-cell transcriptomic data
Conor Delaney et al.
MOLECULAR SYSTEMS BIOLOGY (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer
Niclas C. Blessin et al.
DISEASE MARKERS (2019)
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells
Sema Kurtulus et al.
IMMUNITY (2019)
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
Imran Siddiqui et al.
IMMUNITY (2019)
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody
Danbee Ha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Sarah E. Josefsson et al.
CANCER IMMUNOLOGY RESEARCH (2019)
PD-1 and cancer: molecular mechanisms and polymorphisms
Arash Salmaninejad et al.
IMMUNOGENETICS (2018)
Continuous activity of Foxo1 is required to prevent anergy and maintain the memory state of CD8(+) T cells
Arnaud Delpoux et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia
Kemal Catakovic et al.
ONCOIMMUNOLOGY (2018)
Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia
Marina Wierz et al.
BLOOD (2018)
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Roberta Zappasodi et al.
CANCER CELL (2018)
Fas Promotes T Helper 17 Cell Differentiation and Inhibits T Helper 1 Cell Development by Binding and Sequestering Transcription Factor STAT1
Gerd Meyer zu Horste et al.
IMMUNITY (2018)
被撤回的出版物: CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms (Retracted article. See vol. 132, 2022)
Xian-Yang Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity
Karen O. Dixon et al.
JOURNAL OF IMMUNOLOGY (2018)
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pages et al.
LANCET (2018)
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Sandra P. D'Angelo et al.
LANCET ONCOLOGY (2018)
The personal and clinical utility of polygenic risk scores
Ali Torkamani et al.
NATURE REVIEWS GENETICS (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
Iris Koopmans et al.
ONCOIMMUNOLOGY (2018)
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Alice L. Hung et al.
ONCOIMMUNOLOGY (2018)
TIGIT: a novel immunotherapy target moving from bench to bedside
Benjamin L. Solomon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
High-dimensional single cell analysis identifies stem-like cytotoxic CD8(+) T cells infiltrating human tumors
Jolanda Brummelman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Induction and transcriptional regulation of the co-inhibitory gene module in T cells
Norio Chihara et al.
NATURE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome
Tenzin Gayden et al.
NATURE GENETICS (2018)
Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types
Angela M. Magnuson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
TIM-3, a promising target for cancer immunotherapy
Yayi He et al.
ONCOTARGETS AND THERAPY (2018)
Immune Checkpoints as Therapeutic Targets in Autoimmunity
Christopher Paluch et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD226 opposes TIGIT to disrupt Tregs in melanoma
Julien Fourcade et al.
JCI INSIGHT (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Is autoimmunity the Achilles' heel of cancer immunotherapy?
Carl H. June et al.
NATURE MEDICINE (2017)
CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases
Erna-Elise Paulsen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells
Chien-Hsing Chang et al.
CANCER RESEARCH (2017)
Podoplanin is a negative regulator of Th17 inflammation
Alyssa N. Nylander et al.
JCI INSIGHT (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
Monica Khunger et al.
JCO PRECISION ONCOLOGY (2017)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al.
ANNALS OF ONCOLOGY (2016)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155
Baofu Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor
Silvio Roncella et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
IL-17 Blockade in Psoriasis
Patrick R. Burkett et al.
CELL (2016)
A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
Meromit Singer et al.
CELL (2016)
T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
Yaxian Kong et al.
CLINICAL CANCER RESEARCH (2016)
T cell exhaustion and immune-mediated disease - the potential for therapeutic exhaustion
Eoin F. McKinney et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
Andrea Schietinger et al.
IMMUNITY (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Myeloid cell transmigration across the CNS vasculature triggers IL-1β-driven neuroinflammation during autoimmune encephalomyelitis in mice
Sebastien A. Levesque et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Protein C receptor (PROCR) is a negative regulator of Th17 pathogenicity
Yasuhiro Kishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention
Karsten Mahnke et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase
Takashi Inozume et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Se Jin Im et al.
NATURE (2016)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Autoimmune diseases - connecting risk alleles with molecular traits of the immune system
Maria Gutierrez-Arcelus et al.
NATURE REVIEWS GENETICS (2016)
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
Katrin Klocke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The epigenetic landscape of T cell exhaustion
Debattama R. Sen et al.
SCIENCE (2016)
Re-examining the Nature and Function of Self-Reactive T cells
David M. Richards et al.
TRENDS IN IMMUNOLOGY (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness
Tuoqi Wu et al.
SCIENCE IMMUNOLOGY (2016)
Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy
Gail D. Sckisel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Single-Cell Genomics Unveils Critical Regulators of Th17 Cell Pathogenicity
Jellert T. Gaublomme et al.
CELL (2015)
Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity
Patrick R. Burkett et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients
Joe-Marc Chauvin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
TIGIT predominantly regulates the immune response via regulatory T cells
Sema Kurtulus et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
Alison M. Paterson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells
Pablo Penaloza-MacMaster et al.
JOURNAL OF IMMUNOLOGY (2015)
T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
Eoin F. McKinney et al.
NATURE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases
Maria A. V. Willrich et al.
TRANSLATIONAL RESEARCH (2015)
Podoplanin negatively regulates CD4(+) effector T cell responses
Anneli Peters et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang et al.
NATURE (2015)
Interferon-β Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting Cells
Nicolas Boivin et al.
PLOS ONE (2015)
Clinical blockade of PD1 and LAG3-potential mechanisms of action
Linh T. Nguyen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
Julien Fourcade et al.
CANCER RESEARCH (2014)
LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
Feng Xu et al.
CANCER RESEARCH (2014)
Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
Nicole Joller et al.
IMMUNITY (2014)
Lymphocyte Activation Gene-3 (LAG-3) Negatively Regulates Environmentally-Induced Autoimmunity
Vibha Jha et al.
PLOS ONE (2014)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
The B7-Independent Isoform of CTLA-4 Functions To Regulate Autoimmune Diabetes
Melanie Stumpf et al.
JOURNAL OF IMMUNOLOGY (2013)
The Influence of T Cell Ig Mucin-3 Signaling on Central Nervous System Autoimmune Disease Is Determined by the Effector Function of the Pathogenic T Cells
Sarah Y. Lee et al.
JOURNAL OF IMMUNOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer
Jianwen Bai et al.
TUMOR BIOLOGY (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Impaired Expression of Tim-3 on Th17 and Th1 Cells in Psoriasis
Yasumasa Kanai et al.
ACTA DERMATO-VENEREOLOGICA (2012)
The functional cytotoxic T lymphocyte-associated Protein 4 49G-to-A genetic variant and risk of pancreatic cancer
Ming Yang et al.
CANCER (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Exploiting the Mutanome for Tumor Vaccination
John C. Castle et al.
CANCER RESEARCH (2012)
Dysregulated Tim-3 expression and its correlation with imbalanced CD4 helper T cell function in ulcerative colitis
Fengmin Shi et al.
CLINICAL IMMUNOLOGY (2012)
T-Cell Immunoglobulin- and Mucin-Domain-Containing Molecule 3 Gene Polymorphisms and Renal Cell Carcinoma
Chen Cai et al.
DNA AND CELL BIOLOGY (2012)
Functional Exhaustion of CD4+ T Lymphocytes during Primary Cytomegalovirus Infection
Pierre Antoine et al.
JOURNAL OF IMMUNOLOGY (2012)
Association of CTLA-4 gene polymorphisms with sporadic breast cancer risk and clinical features in Han women of Northeast China
Dalin Li et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2012)
T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer
Danian Tong et al.
MOLECULAR BIOLOGY REPORTS (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Induction and molecular signature of pathogenic TH17 cells
Youjin Lee et al.
NATURE IMMUNOLOGY (2012)
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion
Manu Rangachari et al.
NATURE MEDICINE (2012)
Transcriptional control of effector and memory CD8+ T cell differentiation
Susan M. Kaech et al.
NATURE REVIEWS IMMUNOLOGY (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Vstm3 is a member of the CD28 family and an important modulator of T-cell function
Steven D. Levin et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
TIM polymorphisms-genetics and function
J. Lee et al.
GENES AND IMMUNITY (2011)
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Lukas Baitsch et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Nicole Joller et al.
JOURNAL OF IMMUNOLOGY (2011)
Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3
Maria Bettini et al.
JOURNAL OF IMMUNOLOGY (2011)
Fate mapping of IL-17-producing T cells in inflammatory responses
Keiji Hirota et al.
NATURE IMMUNOLOGY (2011)
Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity
Ying Liu et al.
CLINICAL IMMUNOLOGY (2010)
Involvement of T cell Ig Mucin-3 (Tim-3) in the negative regulation of inflammatory bowel disease
Xia Li et al.
CLINICAL IMMUNOLOGY (2010)
T-bet, a Th1 transcription factor regulates the expression of Tim-3
Ana C. Anderson et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
Valerie Dardalhon et al.
JOURNAL OF IMMUNOLOGY (2010)
T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells
Rosemarie H. DeKruyff et al.
JOURNAL OF IMMUNOLOGY (2010)
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Kamran Ghoreschi et al.
NATURE (2010)
Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF
Michael Quigley et al.
NATURE MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility to multiple autoimmune diseases
Amit K. Maiti et al.
RHEUMATOLOGY (2010)
Genetic Polymorphisms in Cytotoxic T-Lymphocyte Antigen 4 and Cancer: The Dialectical Nature of Subtle Human Immune Dysregulation
Tong Sun et al.
CANCER RESEARCH (2009)
TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines
William D. Hastings et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
Kent S. Boles et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
CD226 Gly307Ser association with multiple autoimmune diseases
J. P. Hafler et al.
GENES AND IMMUNITY (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Th1, Th17, and Th9 Effector Cells Induce Experimental Autoimmune Encephalomyelitis with Different Pathological Phenotypes
Anneli Jaeger et al.
JOURNAL OF IMMUNOLOGY (2009)
Genetic Evidence That the Differential Expression of the Ligand-Independent Isoform of CTLA-4 Is the Molecular Basis of the Idd5.1 Type 1 Diabetes Region in Nonobese Diabetic Mice
Manabu Araki et al.
JOURNAL OF IMMUNOLOGY (2009)
Enhancing SIV-specific immunity in vivo by PD-1 blockade
Vijayakumar Velu et al.
NATURE (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis
Masako Seki et al.
CLINICAL IMMUNOLOGY (2008)
Role of Th1 and Th17 cells in organ-specific autoimmunity
Valerie Dardalhon et al.
JOURNAL OF AUTOIMMUNITY (2008)
CTLA-4 Is a Direct Target of Wnt/β-Catenin Signaling and Is Expressed in Human Melanoma Tumors
Kavita V. Shah et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine M. Koebel et al.
NATURE (2007)
TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology
Mandy J. McGeachy et al.
NATURE IMMUNOLOGY (2007)
LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems
Joseph F. Grosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Molecular signature of CD8+ T cell exhaustion during chronic viral infection
E. John Wherry et al.
IMMUNITY (2007)
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation
Thomas Korn et al.
NATURE MEDICINE (2007)
IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis
Paresh Thakker et al.
JOURNAL OF IMMUNOLOGY (2007)
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients
Maher K. Gandhi et al.
BLOOD (2006)
A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis
Caroline Sutton et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Dysregulated T cell expression of TIM3 in multiple sclerosis
Ken Koguchi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity
C Casati et al.
CANCER RESEARCH (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Anti-TNF-alpha antibody therapies in autoimmune diseases
Kokona Chatzantoni et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2006)
Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population
Sang-Hoon Lee et al.
ARTHRITIS RESEARCH & THERAPY (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
E Contardi et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Adaptive immune responses in acute and chronic hepatitis C virus infection
DG Bowen et al.
NATURE (2005)
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes
J Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Association of the CTLA-4 gene with rheumatoid arthritis in Chinese Han population
C Lei et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2005)
Inverse correlation between IL-7 receptor expression and CD8 T cell exhaustion during persistent antigen stimulation
KS Lang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
CL Langrish et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Effector function of human tumor-specific CD8 T cells in melanoma lesions:: A state of local functional tolerance
A Zippelius et al.
CANCER RESEARCH (2004)
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C Blank et al.
CANCER RESEARCH (2004)
Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis
E Bettelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Antigen-independent memory CD8 T cells do not develop during chronic viral infection
EJ Wherry et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Memory CD8 T-cell differentiation during viral infection
EJ Wherry et al.
JOURNAL OF VIROLOGY (2004)
Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope
L Prokunina et al.
ARTHRITIS AND RHEUMATISM (2004)
Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine
YF He et al.
JOURNAL OF IMMUNOLOGY (2004)
An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells
L Vijayakrishnan et al.
IMMUNITY (2004)
Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease
Y Ban et al.
GENES AND IMMUNITY (2003)
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis
AD Salama et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
H Ueda et al.
NATURE (2003)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment
EJ Wherry et al.
JOURNAL OF VIROLOGY (2003)
Lineage relationship and protective immunity of memory CD8 T cell subsets
EJ Wherry et al.
NATURE IMMUNOLOGY (2003)
Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production
JA Brown et al.
JOURNAL OF IMMUNOLOGY (2003)
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance
CA Sabatos et al.
NATURE IMMUNOLOGY (2003)
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance
A Sanchez-Fueyo et al.
NATURE IMMUNOLOGY (2003)
Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes
C Nielsen et al.
TISSUE ANTIGENS (2003)
A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans
L Prokunina et al.
NATURE GENETICS (2002)
Projection of an immunological self shadow within the thymus by the aire protein
MS Anderson et al.
SCIENCE (2002)
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues
M Ishida et al.
IMMUNOLOGY LETTERS (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
C Lock et al.
NATURE MEDICINE (2002)
The roles of IFNγ in protection against tumor development and cancer immunoediting
H Ikeda et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self
J Derbinski et al.
NATURE IMMUNOLOGY (2001)
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3):: role of LAG-3/MHC class II interactions in cell-cell contacts
CE Demeure et al.
EUROPEAN JOURNAL OF CANCER (2001)
The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFNγ
TJ Paradis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2001)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
CTLA-4 in autoimmune diseases - a general susceptibility gene tc autoimmunity?
OP Kristiansen et al.
GENES AND IMMUNITY (2000)
Share Paper
